2019
March 15: NORTHLAND Signs a Clinical Research Cooperation Agreement with Kun Tuo Xin Cheng
July 5: Huienland Olopatadine Hydrochloride Eye Drops Received the Notice of Acceptance for Drug Registration.
July 16: Hyaluronic Acid Sodium Eye Drops from Huienland have received drug registration approval.
August 18: NL003 Phase III Clinical Trial Investigator Meeting
November 8: NL005 Phase IIa Clinical Trial Protocol Discussion Meeting
December 30: The Huienland single-dose eye drop production line has passed GMP certification.



